ADRIAN AGAPITO: Open Payments
NPI 1790123495 · EDINBURG, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$53,337 in 120 payments from 12 companies in 2025. Trend: 2023 $1,130 · 2024 $23,073 · 2025 $53,337
Speaker / faculty: $43,986Consulting: $4,500Food & beverage: $2,458Travel & lodging: $2,393
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 41 | $25,854 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 26 | $15,293 |
| Teva Pharmaceuticals USA, Inc. | 17 | $11,488 |
| Corium, LLC | 13 | $203 |
| Axsome Therapeutics, Inc. | 4 | $170 |
| Otsuka America Pharmaceutical, Inc. | 10 | $150 |
| Alkermes, Inc. | 3 | $63 |
| E.R. Squibb & Sons, L.L.C. | 2 | $33 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $25 |
| Lundbeck LLC | 1 | $24 |
Products named: VRAYLAR, CAPLYTA, UZEDY, Azstarys, Auvelity, REXULTI, ARISTADA, ABILIFY ASIMTUFII.
Industry payments across TX — which companies pay providers there.
